Difference between revisions of "Chidamide (Epidaza)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== HDAC inhibitor ==Preliminary data== ===Peripheral T-cell lymphoma=== # Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, Yu L, Ke X, Huang H, Shen Z,...") |
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
||
Line 4: | Line 4: | ||
==Preliminary data== | ==Preliminary data== | ||
===[[Peripheral T-cell lymphoma]]=== | ===[[Peripheral T-cell lymphoma]]=== | ||
− | # Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, Yu L, Ke X, Huang H, Shen Z, Fan Y, Li W, Zhao X, Qi J, Huang H, Zhou D, Ning Z, Lu X. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015 Aug;26(8):1766-71. Epub 2015 Jun 23. [http://annonc.oxfordjournals.org/content/26/8/1766.long link to original article] [ | + | # Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, Yu L, Ke X, Huang H, Shen Z, Fan Y, Li W, Zhao X, Qi J, Huang H, Zhou D, Ning Z, Lu X. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015 Aug;26(8):1766-71. Epub 2015 Jun 23. [http://annonc.oxfordjournals.org/content/26/8/1766.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26105599 PubMed] |
==History of changes in FDA indication== | ==History of changes in FDA indication== |
Revision as of 02:51, 2 December 2016
Mechanism of action
HDAC inhibitor
Preliminary data
Peripheral T-cell lymphoma
- Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, Yu L, Ke X, Huang H, Shen Z, Fan Y, Li W, Zhao X, Qi J, Huang H, Zhou D, Ning Z, Lu X. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015 Aug;26(8):1766-71. Epub 2015 Jun 23. link to original article PubMed
History of changes in FDA indication
Not FDA approved, but is approved for use in China.
Also known as
HBI-8000